Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 1
2014 4
2015 3
2016 1
2018 3
2019 8
2020 8
2021 3
2022 2
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Ilhan Y, Tatli AM, Teker F, Onder AH, Kose F, Geredeli C, Karaagac M, Kaplan MA, Inanc M, Goktas Aydin S, Kargi A, Arak H, Ozturk B, Besen AA, Selvi O, Korkmaz M, Oruc Z, Bozkurt O, Bilici A, Bayram S, Dae SA, Ozdogan M, Coskun HS, Sezgin Goksu S. Ilhan Y, et al. Among authors: besen aa. Int J Gynecol Cancer. 2022 Apr 4;32(4):502-507. doi: 10.1136/ijgc-2021-003165. Int J Gynecol Cancer. 2022. PMID: 35086927
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Göksu SS, Tatlı AM, Geredeli Ç, Atcı M, Besen AA, Mertsoylu H, Uysal M, Özdoğan M, Aydın SG, Bilici A, Karaağaç M, Artaç M, Kaplan MA, Ebinç S, Coşkun HŞ. Göksu SS, et al. Among authors: besen aa. Cancer Chemother Pharmacol. 2021 Nov;88(5):805-812. doi: 10.1007/s00280-021-04328-9. Epub 2021 Jul 26. Cancer Chemother Pharmacol. 2021. PMID: 34312705
Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Yildirim BA, Onal C, Kose F, Oymak E, Sedef AM, Besen AA, Aksoy S, Guler OC, Sumbul AT, Muallaoglu S, Mertsoylu H, Ozyigit G. Yildirim BA, et al. Among authors: besen aa. Strahlenther Onkol. 2019 Oct;195(10):872-881. doi: 10.1007/s00066-019-01429-6. Epub 2019 Jan 30. Strahlenther Onkol. 2019. PMID: 30701292 Clinical Trial. English.
41 results